Business Context and Reporting Period
This Form 8-K is a current report filed by AVROBIO, Inc. (not Tectonic Therapeutic, Inc.) on December 21, 2018, covering events occurring on December 17 and 18, 2018. The filing primarily addresses significant changes to the company's executive leadership team, including the departure of the Chief Financial Officer and Chief Medical Officer and the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation package for the newly appointed Chief Financial Officer, Erik Ostrowski:
- Base Salary: $412,000 annually.
- Target Annual Incentive: 40% of base salary.
- Signing Bonus: $170,000 cash.
- Restricted Stock Units (RSUs): Value of $36,000 divided by the closing stock price on the start date.
- Stock Options: Option to purchase 186,000 shares, vesting over four years.
Material Changes
The filing reports the following material changes in corporate governance and personnel:
- Departure of CFO: Katina Dorton resigned as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective immediately on December 17, 2018.
- Departure of CMO: Nerissa Kreher, M.D., resigned as Chief Medical Officer and executive officer, effective immediately on December 17, 2018. She will serve as a senior advisor until March 31, 2019.
- Appointment of New CFO: Erik Ostrowski was appointed as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective January 2, 2019.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the leadership changes. The company issued a press release on December 18, 2018, titled "AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires," which is included as an exhibit but not detailed in the text of this filing. No specific guidance, risks, or contingencies regarding the company's operational outlook were disclosed in this document.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the context of the "four senior management hires" mentioned.
- Review the full Employment Agreement (Exhibit 10.1) for detailed definitions of "Cause," "Good Reason," and specific change-in-control provisions.
- Confirm the exact number of RSUs granted to Mr. Ostrowski, as the filing only provides the dollar value ($36,000) and requires division by the stock price on the start date.
- Monitor subsequent filings for the appointment of a new Chief Medical Officer to replace Dr. Kreher.